GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Glaxo, Pfizer to Merge Consumer Health Units, Form New JV
by Zacks Equity Research
Glaxo (GSK) and Pfizer agree to merge their consumer healthcare units into a new joint venture (JV) with almost $13 billion in annual sales. Glaxo will eventually spin-off the joint venture.
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.
Gilead's (GILD) Harvoni and Descovy Get Approval in China
by Zacks Equity Research
Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.
GlaxoSmithKline (GSK) Stock Moves -0.7%: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $38.34, marking a -0.7% move from the previous day.
Gilead (GILD) Announces Data on CAR T Therapy Candidate
by Zacks Equity Research
Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
Company News For Dec 4, 2018
by Zacks Equity Research
Companies In The News Are: TSRO,GSK,TRCO,NXST,VNDA,GBT
Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%
by Zacks Equity Research
Glaxo (GSK) announces definitive deal to buy TESARO.
TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer
by Zacks Equity Research
TESARO (TSRO) receives an acquisition offer from London-based pharma giant, Glaxo, valuing the company at $75 a share. Total value of the deal stands at $5.1 billion which includes acquisition of debt.
Glaxo to Sell India's Popular Horlicks Brand to Unilever
by Zacks Equity Research
Glaxo (GSK) divests its Horlicks and other nutrition products in India to Unilever.
Key Pharma Players With HIV Focus Ahead of World Aids Day
by Indrajit Bandyopadhyay
We take a look at some of the major pharma companies in the HIV market that are developing drugs to address the life-threatening disease.
Merck (MRK) Receives Approval for 2 HIV Medicines in EU
by Zacks Equity Research
Merck's (MRK) two new HIV drugs, Pifeltro and Delstrigo, containing doravirine, get approval in EU.
4 Big Pharma Stocks to Add to Your Portfolio in December
by Kinjel Shah
The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.
Novartis (NVS) Receives EC Approval for Neulasta Biosimilar
by Zacks Equity Research
Novartis (NVS) obtains EC approval for Ziextenzo, the biosimilar of Amgen's Neulasta.
What Makes GlaxoSmithKline (GSK) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does GlaxoSmithKline (GSK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Glaxo's Horlicks Sale Bid Heats Up, Nestle, Unilever Close In
by Zacks Equity Research
Per a Financial Times report, Glaxo (GSK) is in exclusive talks with Unilever to sell its Horlicks brand in India. Another report in an India-based newspaper says Nestle is close to buying Horlicks.
Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease
by Zacks Equity Research
AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.
3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far
by Zacks Equity Research
Glaxo's (GSK) shares have outperformed the industry this year. Here are some reasons for the same.
Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan
by Zacks Equity Research
GlaxoSmithKline (GSK) along with partner J&J gains approval for two-drug HIV regimen Juluca from the Japanese Ministry of Health, Labour and Welfare to benefit patients in the country.
Glaxo Inks Marketing Deal for Anaemia Candidate in Japan
by Zacks Equity Research
GlaxoSmithKline (GSK) signs a collaboration contract with Japan's Kyowa Hakko Kirin for future commercialization of daprodustat in Japan.
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth
by Zacks Equity Research
Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.
Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?
by Zacks Equity Research
Let???s see if GlaxoSmithKline plc (GSK) stock is a good choice for value-oriented investors right now from multiple angles.
Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs
by Zacks Equity Research
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs
FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz
by Zacks Equity Research
The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Gilead's Vemlidy Gets Approval in China for HBV Infection
by Zacks Equity Research
Gilead (GILD) obtains approval for Vemlidy in China for the treatment of chronic hepatitis B in adults and adolescents.